Garg Pushkal

EVP Chief R&DALNYLAM PHARMACEUTICALS, INC. (ALNY) · full profile →Form 4 · filed Mar 6, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.5M
Net Open-Market Flow
-$1.5M
Transactions
12
12 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 5, 2026Sell(S)740$323.55$239K20K
Mar 5, 2026Sell(S)654$322.33$211K20K
Mar 5, 2026Sell(S)500$326.08$163K19K
Mar 5, 2026Sell(S)510$324.59$166K19K
Mar 4, 2026Sell(S)767$323.84$248K22K
Mar 4, 2026Sell(S)350$323.01$113K22K
Mar 4, 2026Sell(S)289$321.82$93K23K
Mar 4, 2026Sell(S)106$319.03$34K23K
Mar 4, 2026Sell(S)215$320.81$69K23K
Mar 4, 2026Sell(S)102$320.01$33K23K
Mar 4, 2026Sell(S)208$325.67$68K21K
Mar 4, 2026Sell(S)272$324.88$88K21K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001735276-26-000063) within minutes of acceptance. Every field above traces to the original document. Verify it directly: